Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer s Revenues, Income Rise in First Quarter

NEW YORK, April 23 (GenomeWeb News) - PerkinElmer reported a 10 percent increase in year-over-year revenues in the first quarter of 2004, with 7 percent growth in its Life and Analytical Sciences division.

 

The company took in $393.5 million in the quarter, compared with $358.4 million in the same period last year. Revenues in LAS were $249.2 million, compared with $232.2 million in the year-ago period. The LAS division represented 63 percent of PerkinElmer's total revenues in Q1 2004.

 

During a conference call today discussing its quarterly earnings, Robert Friel, the company's chief financial officer, attributed much of the LAS growth in the Biopharma subdivision to strength in high-throughput screening, liquid handling, and proteomics.

 

PerkinElmer reported a hefty increase in net income as well. Income climbed to $13.3 million, or $.10 per share, from $2.4 million, or $.02 per share in the year-ago period.

 

The company's R&D spending increased to $241.5 million in Q1 2004, compared with $219.3 million in Q1 2003.

 

As of March 28, 2004, PerkinElmer had cash and cash equivalents of $165.5 million.

 

 

 

 

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.